{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:45:05Z","timestamp":1792424705976,"version":"4.5.0"},"reference-count":32,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Kidney transplantation is associated with an increased risk of renal cell carcinoma (RCC). This study aimed to evaluate the outcomes of de novo RCC in kidney transplant recipients (KTRs). Methods: We retrospectively identified 50 de novo RCC cases among 4012 KTRs transplanted from 2005 to 2024. Data on patient characteristics and outcomes were collected. Propensity score matching (PSM) compared 34 localized RCC cases in KTRs with 34 non-transplant RCC cases. The statistical analyses used Kaplan\u2013Meier estimates, the log-rank test, and the Cox regression. Results: The RCC incidence was 0.64 per 1000 person-years, with a standardized incidence ratio of 4.40 (95% CI: 3.33\u20135.80). In the KTR cohort, clear cell RCC was present in 42%, and papillary RCC was present in 42%. RCC developed predominantly in native kidneys (92%). UICC stage I was present in 74%. The treatment for the non-metastatic RCC was nephrectomy in the majority of cases (91%). For the metastatic RCC, 71% received a tyrosine kinase inhibitor (TKI). In the KTR cohort, the 3- and 5-year overall survival (OS) rates were 85% and 72%, respectively, with a median OS of 199 months; the synchronous metastasized (M1) patients had a median OS of 14 months. Rejection, age, advanced UICC stage, higher pT stage, clinical positive lymph nodes, M1, and higher grade were significantly associated with poor OS. The 5-year OS (96% vs. 84%, p = 0.72) and MFS (92% vs. 93%, p = 0.61) were comparable in the PSM cohort between the KTRs and the non-KTRs in the localized RCC. Conclusions: KTRs have a higher risk of RCC and present at a localized stage with comparable OS rates to non-transplant RCC patients. Adverse tumor characteristics, including synchronous metastases, significantly affect the prognosis, highlighting the need for surveillance and individualized treatment, particularly for metastatic RCC.<\/jats:p>","DOI":"10.3390\/cancers17132200","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T06:18:36Z","timestamp":1751264316000},"page":"2200","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["De Novo Renal Cell Carcinoma in Kidney Transplant Recipients: Incidence, Outcomes, and Therapeutic Challenges"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0319-5002","authenticated-orcid":false,"given":"Jacob","family":"Schmidt","sequence":"first","affiliation":[{"name":"Charit\u00e9\u2014Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Department of Urology, 12203 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Lehnert","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Department of Urology, 12203 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Lichy","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Department of Urology, 12203 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Plage","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Department of Urology, 12203 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Jeutner","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Department of Urology, 12203 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-2877","authenticated-orcid":false,"given":"Lukas","family":"Kurz","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Department of Urology, 12203 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7226-3852","authenticated-orcid":false,"given":"Bernhard","family":"Ralla","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Department of Urology, 12203 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1151-9935","authenticated-orcid":false,"given":"Markus H.","family":"Lerchbaumer","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Department of Radiology, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Schlomm","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Department of Urology, 12203 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Friedersdorff","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Department of Urology, 12203 Berlin, Germany"},{"name":"Department of Urology, Evangelisches Krankenhaus Koenigin Elisabeth Herzberge, 10365 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Maxeiner","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Department of Urology, 12203 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Peters","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Department of Urology, 12203 Berlin, Germany"},{"name":"Department of Urology, Evangelisches Krankenhaus Koenigin Elisabeth Herzberge, 10365 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11934-021-01078-2","article-title":"Urological Cancers and Kidney Transplantation: A Literature Review","volume":"22","author":"Tobia","year":"2021","journal-title":"Curr. Urol. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00120-024-02317-3","article-title":"Urogenital Tumors Following Kidney Transplantation\u2014Monocentric Analysis of Incidences and Overview of Urological Preventive Measures","volume":"63","author":"Putz","year":"2024","journal-title":"Urologie"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15375","DOI":"10.18632\/oncotarget.23841","article-title":"Cancer Risks in Recipients of Renal Transplants: A Meta-Analysis of Cohort Studies","volume":"9","author":"Wang","year":"2018","journal-title":"Oncotarget"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/iju.15588","article-title":"Genitourinary Malignancies in Kidney Transplant Recipients","volume":"31","author":"Okumi","year":"2024","journal-title":"Int. J. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1111\/ajt.13862","article-title":"Risk of Renal Cell Carcinoma Among Kidney Transplant Recipients in the United States","volume":"16","author":"Karami","year":"2016","journal-title":"Am. J. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/TP.0b013e3181a238f6","article-title":"De Novo Cancers Arising in Organ Transplant Recipients Are Associated With Adverse Outcomes Compared With the General Population","volume":"87","author":"Miao","year":"2009","journal-title":"Transplantation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/ajt.14533","article-title":"Urologic Malignancies in Kidney Transplantation","volume":"18","author":"Hickman","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1159\/000509292","article-title":"Nephron Sparing Surgery in Renal Allograft in Recipients with de Novo Renal Cell Carcinoma: Two Case Reports and Review of the Literature","volume":"104","author":"Hubatsch","year":"2020","journal-title":"Urol. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00761-023-01362-5","article-title":"Epidemiologie des Nierenzellkarzinoms in Deutschland 2019","volume":"29","author":"Stang","year":"2023","journal-title":"Onkologie"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1097\/TP.0000000000003762","article-title":"Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review","volume":"106","author":"Dahle","year":"2022","journal-title":"Transplantation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23736\/S2724-6051.22.04881-9","article-title":"Management of Renal Cell Carcinoma in Transplant Kidney: A Systematic Review and Meta-Analysis","volume":"75","author":"Crocerossa","year":"2023","journal-title":"Minerva Urol. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Robinson, S., Nag, A., Peticca, B., Prudencio, T., Di Carlo, A., and Karhadkar, S. (2023). Renal Cell Carcinoma in End-Stage Kidney Disease and the Role of Transplantation. Cancers, 16.","DOI":"10.3390\/cancers16010003"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1007\/s00345-023-04495-9","article-title":"Renal Cell Carcinoma in Kidney Transplant Recipients: Incidence, Trends, Clinical Management & Outcomes","volume":"41","author":"Minkovich","year":"2023","journal-title":"World J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.transproceed.2023.09.010","article-title":"Benefits of Routine Screening for Renal Cell Carcinoma of Native Kidney in Renal Transplant Recipients","volume":"55","author":"Vigara","year":"2023","journal-title":"Transplant. Proc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e071658","DOI":"10.1136\/bmjopen-2023-071658","article-title":"Screening for Renal Cell Carcinoma in Renal Transplant Recipients: A Single-Centre Retrospective Study","volume":"13","author":"Yohannan","year":"2023","journal-title":"BMJ Open"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Tao, Y., Wang, J., Peng, Y., and Zhou, J. (2025). Renal Cell Carcinoma of the Native Kidney in Renal Transplant Recipients: Case Report and Literature Review. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1536411"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Aveta, A., Iossa, V., Spena, G., Conforti, P., Pagano, G., Dinacci, F., Verze, P., Manfredi, C., Ferro, M., and Lasorsa, F. (2024). Ablative Treatments for Small Renal Masses and Management of Recurrences: A Comprehensive Review. Life, 14.","DOI":"10.3390\/life14040450"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.transproceed.2011.03.068","article-title":"Renal Cell Carcinoma of the Native Kidney: A Frequent Tumor After Kidney Transplantation With Favorable Prognosis in Case of Early Diagnosis","volume":"43","author":"Toronyi","year":"2011","journal-title":"Transplant. Proc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"773","DOI":"10.21873\/anticanres.11376","article-title":"De Novo Renal Cell Carcinoma of Native Kidneys in Renal Transplant Recipients: A Single-Center Experience","volume":"37","author":"Moris","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4081\/rt.2017.6550","article-title":"Renal Cancer in Recipients of Kidney Transplant","volume":"9","author":"Dhakal","year":"2017","journal-title":"Rare Tumors"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1464-410X.2010.09856.x","article-title":"De Novo Renal Cell Carcinoma of Native and Graft Kidneys in Renal Transplant Recipients","volume":"108","author":"Tsaur","year":"2011","journal-title":"BJU Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.21037\/atm.2019.01.08","article-title":"Is Active Surveillance an Option for Metachronous Metastatic Renal Cell Carcinoma?","volume":"7","author":"Ficarra","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_24","unstructured":"Breda, A., Budde, K., Figueiredo, A., Garc\u00eda, E.L., Olsburgh, J., Regele, H., and Zakri, R.H. (2024). Eau Guidelines on Renal Transplantation, EAU Guidelines Office."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Tufano, A., Drudi, F.M., Angelini, F., Polito, E., Martino, M., Granata, A., Di Pierro, G.B., Kutrolli, E., Sampalmieri, M., and Canale, V. (2022). Contrast-Enhanced Ultrasound (CEUS) in the Evaluation of Renal Masses with Histopathological Validation\u2014Results from a Prospective Single-Center Study. Diagnostics, 12.","DOI":"10.3390\/diagnostics12051209"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1002\/cam4.5394","article-title":"Allograft Rejection Following Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients: A Safety Analysis from a Literature Review and a Pharmacovigilance System","volume":"12","author":"Cui","year":"2023","journal-title":"Cancer Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"102082","DOI":"10.1016\/j.eucr.2022.102082","article-title":"Metastatic Renal Cell Carcinoma of the Native Kidney in a Renal Transplant Recipient: Revisiting the Era of Tyrosine Kinase Inhibitors\u2014Case Report","volume":"43","author":"Chavarriaga","year":"2022","journal-title":"Urol. Case Rep."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Studentova, H., Spisarova, M., Kopova, A., Zemankova, A., Melichar, B., and Student, V. (2023). The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15153855"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1111\/ajt.14238","article-title":"Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients","volume":"17","author":"Krisl","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/TP.0000000000002914","article-title":"Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients","volume":"104","author":"Venkatachalam","year":"2020","journal-title":"Transplantation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.acuro.2023.03.007","article-title":"How to Manage Renal Masses in Kidney Transplant Recipients? A Collaborative Review by the EAU-YAU Kidney Transplantation and Renal Cancer Working Groups","volume":"47","author":"Andras","year":"2023","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2200\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:54Z","timestamp":1760032914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":32,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cancers17132200"],"URL":"https:\/\/doi.org\/10.3390\/cancers17132200","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}